Dataset from A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination

The aim of this study is to evaluate the immune response and safety of both GlaxoSmithKline
Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years
of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy
adults 18 YOA and older, when administered sequentially or co-administered with Moderna's
mRNA-1273 booster vaccination against COVID-19.